Predictive factors of radiation therapy for patients with prostate specific antigen recurrence after radical prostatectomy

Objective  To assess the efficacy of salvage/adjuvant radiation therapy (RT) for patients with prostate‐specific antigen (PSA) recurrence after radical prostatectomy (RP).

[1]  E. B. Butler,et al.  Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  P. Carroll,et al.  Management of a positive surgical margin after radical prostatectomy: decision analysis. , 2000, The Journal of urology.

[3]  L. Vanuytsel,et al.  Radiotherapy for PSA Recurrence after Radical Prostatectomy , 2000, European Urology.

[4]  E. Bergstralh,et al.  Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin. , 2000, The Journal of urology.

[5]  D W Hillman,et al.  Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. , 2000, The Journal of urology.

[6]  P. Carroll,et al.  Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns. , 1999, Urology.

[7]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[8]  R. Valicenti,et al.  The efficacy of early adjuvant radiation therapy for pT3N0 prostate cancer: a matched-pair analysis. , 1999, International journal of radiation oncology, biology, physics.

[9]  R. Parker,et al.  Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy. , 1998, The cancer journal from Scientific American.

[10]  M. Bagshaw.  Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer , 1998, International journal of radiation oncology, biology, physics.

[11]  J. Forman,et al.  Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy. , 1998, Urology.

[12]  N. Sanfilippo,et al.  Preirradiation PSA predicts biochemical disease-free survival in patients treated with postprostatectomy external beam irradiation. , 1997, International journal of radiation oncology, biology, physics.

[13]  J. Forman,et al.  Therapeutic irradiation for patients with an elevated post-prostatectomy prostate specific antigen level. , 1997, The Journal of urology.

[14]  S. Schild,et al.  The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy. , 1996, The Journal of urology.

[15]  V. Hárs,et al.  Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy. , 1996, Urology.

[16]  S. Groshen,et al.  Impact of moderate dose of postoperative radiation on urinary continence and potency in patients with prostate cancer treated with nerve sparing prostatectomy. , 1996, The Journal of urology.

[17]  M. Kattan,et al.  Prognostic significance of positive surgical margins in radical prostatectomy specimens. , 1995, The Journal of urology.

[18]  M. Anscher,et al.  Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate: ten-year update. , 1995, International journal of radiation oncology, biology, physics.

[19]  A. D'Amico,et al.  A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. , 1995, The Journal of urology.

[20]  M. Dauge,et al.  Effect of radiation therapy after radical prostatectomy on serum prostate-specific antigen measured by an ultrasensitive assay. , 1995, Urology.

[21]  G. Montana,et al.  The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen. , 1995, International journal of radiation oncology, biology, physics.

[22]  W. Catalona,et al.  Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: early versus delayed treatment. , 1994, The Journal of urology.

[23]  A. Partin,et al.  Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. , 1994, Urology.

[24]  Galina Pizov,et al.  Correlation of pathologic findings with progression after radical retropubic prostatectomy , 1993, Cancer.

[25]  J. Oesterling,et al.  Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. , 1991, The Journal of urology.

[26]  J. Epstein.  Evaluation of Radical Prostatectomy Capsular Margins of Resection: The Significance of Margins Designated as Negative, Closely Approaching, and Positive , 1990, The American journal of surgical pathology.

[27]  J. Smith,et al.  Postoperative radiation therapy for pathologic stage C prostate cancer. , 1987, International journal of radiation oncology, biology, physics.

[28]  M. Pilepich,et al.  Postoperative irradiation in carcinoma of the prostate. , 1984, International journal of radiation oncology, biology, physics.

[29]  J. Cadeddu,et al.  Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. , 1998, The Journal of urology.

[30]  S. Cha,et al.  Irradiation for locally recurrent carcinoma of the prostate following radical prostatectomy. , 1997, Urology.

[31]  A. Zietman,et al.  Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. , 1997, International journal of radiation oncology, biology, physics.

[32]  S. Levitt,et al.  Delayed/salvage radiation therapy in patients with elevated prostate specific antigen levels after radical prostatectomy. A long term follow-up. , 1996, Cancer.

[33]  M. Hafermann,et al.  Adjuvant radiotherapy following radical prostatectomy: results and complications. , 1986, The Journal of urology.